Paul A. Liberti
CEO & Chief Scientific Officer

EDUCATION:

Postdoc – National Institute for Medical Research (NIMR):    

                      Antibody characterization, binding structure                      

Postdoc Fellowship NJ College of Medicine                                        

PhD – Stevens Institute of Technology: Physical Chemistry:

                      Polymer and Polyelectrolyte Chemistry                            

MS – Loyola University Chicago Stritch School of Medicine:

                      Biochemistry                                                                                  

AB – Columbia University: Chemistry

Dr. Liberti is the innovative mastermind behind BioMagnetic Solutions. Towards the end of teaching Biochemistry and Immunology at Thomas Jefferson Medical for 17 years he founded Immunicon, where he invented biologically-active, nanomagnetic ferrofluids (FF), high gradient magnetic devices, and developed other cell separation technologies. Dr. Liberti holds over 30 seminal U.S. patents in these areas, and is well known and respected in this field. He led Immunicon to discover that these ferrofluids could be used in rare cell analysis, which, alongside a team of fellow brilliant scientists across the world, led to the development of the CELLSEARCH® Circulating Tumor Cell (CTC) Test. In 2008, Johnson & Johnson acquired Immunicon, and in 2009 CELLSEARCH® was honored with the prestigious Prix Galien USA Award.

Amidst being the CEO and President of Immunicon and before founding BioMagnetic Solutions, Dr. Liberti consulted and helped manage startups and emerging biotech firms with finance advice, business development, patent strategy, technology development, and more.

In 2011 Dr. Liberti co-founded BioMagnetic Solutions, which utilizes the proprietary ferrofluids he invented at Immunicon in a variety of cell separation applications. At BioMagnetic Solutions he continued inventing and developed two cell separation platforms, X-GRAFFE: a Clinical-Scale Cell Separation System, and FEOSS: a radically faster cell separation platform. To this day Dr. Liberti manages the company’s patent portfolio, brainstorms and advises the scientists on new products and applications, and guides the company through new business endeavors.